PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Inclusion Criteria: * Signed informed consent * Age greater or equal to 18 years * Both sexes * Women of childbearing age with birth control method * Diagnosis of Primary open-angle glaucoma (according to the Guidelines of the Preferred Practice Pattern of the American Academy of Ophthalmology) or ocular hypertension (OHT) * Intraocular pressure (IOP) not controlled with dual therapy according to the principal investigator (PI) judgment. * IOP on the selection visit at 9 am, after the washing period, from 21 - 36 mmHg in at least one eye. Exclusion Criteria: General criteria * Pregnant, breastfeeding or planning to get pregnant women. * Women of childbearing age and who do not intake a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction. * Participation in another clinical research study greater or equal 30 days before the screening visit. * People who cannot comply with their attendance at appointments or with all the - Protocol requirements Medical and therapeutic criteria: * Anterior chamber angle grade less than 2 of Shaffer rating. * Excavation of optic nerve greater than 0.80 horizontal or vertical (ratio cup-disc) * Serious loss of central visual field in any eye (sensitivity less or equal to 10 decibels in greater or equal to 2 of 4 points of the visual field test close to the fixation point) * People not able to safely suspend ocular hypotensives drug products for the washout period according to the PI judgement. * Chronic, recurrent, or active ocular inflammatory diseases (e.g. uveitis, scleritis, keratitis, herpetic) in any eye. * Eye trauma less or equal to 6 months prior to the study * Eye infection / inflammation less or equal to 3 months prior to the study * Clinically significant or progressive retinal disease (e.g. degenerations, diabetic retinopathy, retinal detachment) * Ability Visual 20/200 or worse in any of the eyes. * Subject with only one eye * Eye diseases that contraindicate the use of Beta-blocker (BB) Alpha-adrenergic agonist (AA) or Carbonic anhydrase inhibitors (CAIs) * Intraocular surgery less or equal to 6 months prior to the study * Laser intraocular surgery less or equal to 3 months prior to the study * Any abnormality preventing reliable applanation tonometry * Unstable or uncontrolled cardiovascular disease * Chronic pulmonary disease (e.g. bronchial asthma) * Any condition or illness that do not fit the subject for the study according to the PI judgment. * Use of high doses of salicylate (1 g daily) less or equal to4 weeks before the eligibility visit * In treatment with psychotropic medications that increase the adrenergic response * Known hypersensitivity to BB medications (e.g. timolol), AA (e.g. brimonidine) and CAI (e.g. dorzolamide), sulfonamide derivatives, or any of the components of the study drugs * Concomitant use of monoamine oxidase inhibitors * Systemic or topical use of corticosteroids